As the world experiences a global pandemic of SARS-CoV-2 – the novel coronavirus that causes COVID-19 – it may be instructional to look at the last major pandemic, the H1N1 influenza pandemic of 2009.

Seqirus snagged U.S. FDA approval for Fluad Quadrivalent, the first quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.

As the world prepares for a potential coronavirus pandemic, the U.S. government has been busy making preparations for the possibility of a flu pandemic. The U.S. Food and Drug Administration approved Seqirus’ Audenz, a vaccine for a potential pandemic associated with the H5N1 flu virus.

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.

Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications.

In a late-stage study, Genentech’s flu drug Xofluza showed significant efficacy as a preventative treatment.

Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.

Cambridge, Mass.-based Moderna announced the publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0.

In GlaxoSmithKline’s first-quarter 2019 report was an announcement that the global pharma giant cut the development of two vaccine programs – one for strep pneumonia and the other for a universal flu vaccine.

IQVIA – a leader in human data science – provides consumers with quick and easy access to seasonal suffering data, giving them unique insights into important health related information. Recent data show that flu season is hitting hard in several key markets.